The gynaecology waiting list is rising again. Treating it as one queue is part of the problem

Posted in partnership with Spital Clinic

The list in England has grown for five months running while the overall elective backlog falls. Diagnosis and treatment are separate bottlenecks, and a single headline number hides which one is binding.

The Royal College of Obstetricians and Gynaecologists reported on 16 October that the gynaecology waiting list in England stood at 585,378 in the August 2026 NHS England data, having risen for five consecutive months.

More than 12,800 patients had waited over a year. Fewer than 60 per cent were seen within the 18-week standard, against an average above 65 per cent across elective specialties.

Dr Alison Wright, the College’s president, put the contrast plainly: the overall elective waiting list is coming down, but that is not the story for women and for gynaecology.

A declaration of interest. Spital Clinic provides private gynaecology appointments and scans in London, and therefore operates in the space this shortfall creates.

The argument below is not that private provision solves it.

This has been written about a great deal, and the diagnosis offered is usually some combination of underfunding, workforce shortage and the historic deprioritisation of women’s health.

All three are real. What gets less attention is a structural point about the number itself, which matters because it determines which solutions look promising.

One number, two different queues

The referral-to-treatment figure measures a pathway, not a bottleneck.

A woman referred with heavy bleeding, suspected fibroids, pelvic pain or abnormal bleeding usually needs something looked at before anything can be decided. A scan, sometimes a hysteroscopy, sometimes both. Only after that does a treatment decision exist to be waited for.

So the list contains two populations with very little in common. One is waiting to find out what is wrong.

The other already knows and is waiting for theatre capacity, a specialist clinic or a procedure slot. Both appear in the 585,378. Both are counted the same way.

They are not constrained by the same thing. Diagnostic waits are bounded by imaging capacity, sonographer hours and clinic rooms.

Treatment waits are bounded by surgical lists, anaesthetic cover and beds. Those are different resources, procured differently, and they do not respond to the same intervention.

Why the distinction changes the answer

Consider the fixes that circulate most often.

Remote consultation and telemedicine have been widely proposed, and they are genuinely useful for triage, for follow-up, for menopause and medication reviews, and for the large share of gynaecology that is a conversation rather than a procedure.

For a woman whose pathway is stalled because nobody has scanned her pelvis, a video appointment moves her position in a queue without adding the resource she is waiting on.

Women’s health hubs have shown real results, and part of the reason is that the better ones put imaging alongside the clinic rather than referring onward for it.

That is a capacity intervention disguised as a service redesign, and it works because it addresses the diagnostic constraint directly.

None of this argues against remote models. It argues that a single aggregate figure cannot tell commissioners which constraint is binding in their own system, and without that, investment follows whichever solution is most visible rather than whichever is most limiting.

Separating diagnostic waits from treatment waits in published data would be a modest change with disproportionate value.

It would show where in the pathway time is actually being lost, which varies considerably between trusts, and it would make it far harder to present a redesign that shortens one queue as progress on the whole list.

The number is softer than it looks

There is a second problem, which is that the headline figure is less precise than its six digits imply.

Four NHS trusts did not submit data for the August reporting period.

The figure counts pathways rather than individuals, so a woman referred twice for related problems can appear more than once. RCOG has noted elsewhere that ethnicity recording in this data is incomplete, which means the inequality picture is probably understated rather than overstated.

That last point deserves emphasis, because it is where the human cost concentrates. RCOG analysis published earlier this year found that women in the most deprived areas accounted for 15 per cent of those waiting more than 52 weeks, against 7 per cent from the least deprived.

Over the same period, referrals rose by roughly a quarter. Demand is growing and the waits are falling hardest on the women least equipped to absorb them.

What the independent sector should not claim

It is tempting for a private provider to present same-day diagnostic ultrasound as the answer to a diagnostic bottleneck. The logic is superficially sound and the conclusion is still wrong.

Private capacity is bought by people who can pay for it. The deprivation gradient above describes exactly the women who cannot.

A market operating alongside a rationed public service relieves pressure for those with the shortest effective waits already, and does nothing for the woman at month fourteen in an underserved area.

Framing that as a contribution to the backlog is a marketing claim, not a health one.

What the independent sector can legitimately offer is narrower. It holds operational data on how long diagnostic gynaecology actually takes when it is not queued, which is useful evidence for anyone modelling capacity.

It can be honest about which parts of the pathway are genuinely quick to expand, imaging among them, and which are not.

And it can resist the implication that paying is a solution to a problem defined by who cannot.

The waiting list has risen for five months. Before deciding what would bring it down, it is worth knowing which half of it is growing.